{"drugs":["Lucinactant","Surfaxin"],"mono":{"0":{"id":"930286-s-0","title":"Generic Names","mono":"Lucinactant"},"1":{"id":"930286-s-1","title":"Dosing and Indications","sub":{"1":{"id":"930286-s-1-5","title":"Pediatric Dosing","mono":"<b>Respiratory distress syndrome in the newborn, Prevention:<\/b> 5.8 mL\/kg birth weight INTRATRACHEAL administration in 4 equal aliquots (with infant repositioned between each aliquot) no more frequently than every 6 hours for up to 4 doses in the first 48 hours of life "},"3":{"id":"930286-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Respiratory distress syndrome in the newborn, Prevention<br\/><b>Non-FDA Labeled Indications<\/b><ul><li>Meconium aspiration syndrome<\/li><li>Respiratory distress syndrome in the newborn<\/li><\/ul>"}}},"3":{"id":"930286-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930286-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"930286-s-3-10","title":"Precautions","mono":"<ul><li>adult patients with ARDS; increased risk of death, organ failure, sepsis, renal failure, pulmonary embolism, hypoxia, hypotension, pneumothorax, and\/or anoxic encephalopathy reported during clinical trials; use not recommended<\/li><li>bradycardia, hypoxemia, airway obstruction, or reflux of drug into the endotracheal tube may occur; if reactions occur, interrupt treatment until resolved<\/li><li>intratracheal use only<\/li><li>respiratory status may change rapidly with administration; monitoring recommended, oxygen and ventilatory support modifications may be required<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-332-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930286-s-3-11","title":"Pregnancy Category","mono":"Unknown<br\/>"},{"id":"930286-s-3-12","title":"Breast Feeding","mono":"Unknown<br\/>"}]},"5":{"id":"930286-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Dermatologic:<\/b>Pale complexion<br\/><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Bradyarrhythmia (3% to at least 10%)<\/li><li><b>Respiratory:<\/b>Blocked endotracheal tube, Blood oxygen level abnormal (8% to 17%), Reflux, of drug into endotracheal tube<\/li><\/ul>"},"6":{"id":"930286-s-6","title":"Drug Name Info","sub":{"0":{"id":"930286-s-6-17","title":"US Trade Names","mono":"Surfaxin<br\/>"},"2":{"id":"930286-s-6-19","title":"Class","mono":"Lung Surfactant<br\/>"},"3":{"id":"930286-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"930286-s-7","title":"Mechanism Of Action","mono":"Lucinactant is a sterile, synthetic, non-pyrogenic pulmonary surfactant that compensates for the deficiency of surfactant and restores surface activity to the lungs following endotracheal administration in premature infants, thereby reducing the risk of respiratory distress syndrome.<br\/>"},"9":{"id":"930286-s-9","title":"Administration","mono":"<b>Intratracheal<\/b><br\/><ul><li>for intratracheal administration only<\/li><li>warm the vial of lucinactant intratracheal suspension for 15 minutes in a preheated dry block heater set at 44 degrees C (111 degrees F)<\/li><li>remove the vial from the heater and shake vigorously until suspension is uniform and free-flowing<\/li><li>warmed vials may be stored in the carton at room temperature for up to 2 hours; do not return to the refrigerator after warming<\/li><li>draw up the total dose of lucinactant suspension using a 16- or 18-gauge needle<\/li><li>before administration, ensure patency and proper placement of the endotracheal tube, suction if necessary, and allow the infant to stabilize<\/li><li>position the infant in the right lateral decubitus position with a 30-degree upward incline of the head and thorax<\/li><li>attach the syringe of lucinactant to a 5-French end-hole catheter and thread the catheter through a Bodai valve (or equivalent device)<\/li><li>advance the catheter into the endotracheal tube until the tip is slightly distal to the end of the endotracheal tube<\/li><li>deliver one-fourth of the total dose (first aliquot) while continuing positive pressure mechanical ventilation and maintaining a positive end-expiraratory pressure of 4 to 5 cm H2O<\/li><li>ventilate until the infant is stable (oxygen saturation of at least 90% and heart rate greater than 120 beats\/minute)<\/li><li>repeat the procedure with the infant in the left lateral decubitus position for the second aliquot, right lateral decubitus position for the third aliquot, and left lateral decubitus position for the fourth aliquot<\/li><li>pause between administration of each aliquot to assess the infant's respiratory status<\/li><li>resume usual ventilator management after administration of the fourth aliquot and removal of the catheter<\/li><li>elevate the head of the infant's bed at least 10 degrees for at least 1 to 2 hours, and do not suction the infant for the first hour after dosing unless significant airway obstruction develops<\/li><\/ul>"},"10":{"id":"930286-s-10","title":"Monitoring","mono":"<ul><li>prevention of respiratory distress syndrome in premature infants is evidence of efficacy<\/li><li>oxygen and ventilatory support<\/li><\/ul>"},"13":{"id":"930286-s-13","title":"Clinical Teaching","mono":"Drug may cause apnea, anemia, jaundice, pneumonia, hypotension, hyperglycemia, or bradycardia. <br\/>"}}}